Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

European Journal of Clinical Pharmacology

Volumn 62, Issue 7, 2006, Pages 503-509

  Jaakkola, Tiina ^a   Backman, Janne T ^a   Neuvonen, Mikko ^a   Niemi, Mikko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP2C8; Drug interaction; Montelukast; Pioglitazone; Zafirlukast

Indexed keywords

CYTOCHROME P450 2C8; DRUG METABOLITE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PIOGLITAZONE; PLACEBO; ZAFIRLUKAST;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; VOLUNTEER;

ACETATES; ADMINISTRATION, ORAL; ADULT; ANTI-ASTHMATIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; QUINOLINES; SUBSTRATE SPECIFICITY; THIAZOLIDINEDIONES; TOSYL COMPOUNDS;

EID: 33745727121     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0136-9     Document Type: Article

References (28)

1. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106-1118
2. Eckland DA, Danhof M (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108(Suppl 2):234-242
3. Shen Z, Reed JR, Creighton M, Liu DQ, Tang YS, Hora DF, Feeney W, Szewczyk J, Bakhtiar R, Franklin RB, Vincent SH (2003) Identification of novel metabolites of pioglitazone in rat and dog. Xenobiotica 33:499-509
4. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ (2006) Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 61:70-78
5. Actos product information. Available from: URL: http://www.actos.com/pi. pdf. Accessed Dec 20, 2004
6. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT (2006) Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro; potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol (in press)
7. Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236
8. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691
9. Wang J-S, Neuvonen M, Wen X, Backman JT, Neuvonen PJ (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356
10. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197
11. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626
12. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
13. Wang J-S, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT (1999) Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 85:157-161
14. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131
15. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ (2005) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 77:404-414
16. Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78
17. Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR (2005) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418
18. Lin ZJ, Ji W, Desai-Krieger D, Shum L (2003) Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS. J Pharm Biomed Anal 33:101-108
19. Radhakrishna T, Narasaraju A, Ramakrishna M, Satyanarayana A (2003) Simultaneous determination of montelukast and loratadine by HPLC and derivative spectrophotometric methods. J Pharm Biomed Anal 31:359-368
20. Bui KH, Kennedy CM, Azumaya CT, Birmingham BK (1997) Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 696:131-136
21. Singulair prescribing information. Available from: URL: www.singulair.com/montelukast_sodium/singulair/consumer/adult_asthma/ product_information/pi/index.jsp. Accessed Feb 12, 2006
22. Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ (2006) Telithromycin but not montelukast increases the plasma concentrations and effects of the CYP3A4 and CYP2C8 substrate repaglinide. Clin Pharmacol Ther 79:231-242
23. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305-314
24. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256
25. Dekhuijzen PN, Koopmans PP (2002) Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 41:105-114
26. Markham A, Faulds D (1998) Montelukast. Drugs 56:251-256
27. Accolate prescribing information. Available from: URL: www.astrazeneca-us.com/pi/accolate.pdf. Accessed Feb 12, 2006
28. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H (2005) Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 96:167-175